Concepedia

K. N.

KN

Statistics

Publications

11

Citations

572

H-Index

11

Active since

2000

Affiliations

BC Cancer Agency(Current)

South Texas Accelerated Research Therapeutics

Janssen (United States)

Vancouver General Hospital

K. N. is an author at BC Cancer Agency specializing in pharmacology, oncology, and cancer pharmacology.

Publications per year

2000–2015

11

Publications

11

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

K. N., Martin Gleave, Richard Klasa et al. · PubMed · 2001 · 192 citations

, , +17

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

Hideaki Miyake, K. N., Martin Gleave · PubMed · 2000 · 150 citations

, , +11

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

Bernhard J. Eigl, Scott North, Eric Winquist et al. · Investigational New Drugs · 2015 · 63 citations

, , +7

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Anthony W. Tolcher, K. N., Neal D. Shore et al. · Cancer Chemotherapy and Pharmacology · 2012 · 34 citations · Full text

, , +17

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

K. N., Anthony W. Tolcher, Peter P. Lee et al. · Cancer Chemotherapy and Pharmacology · 2012 · 34 citations

, , +13

1–5 of 11